Genetic and Pharmacologic Targeting of Eya3 in Macrophages Drives Anti-Tumor Immunity in Triple-Negative Breast Cancer.

Authors

Kaiah M Fields, Gabriela Terue Rizzo Kodama, Etienne Danis, Jessica G Olivas-Corral, Sheera R Rosenbaum, Uma Kantheti, Goksu Sarioglu, Erin Citarella, Lars Wick, Kate Matlin, Brooke Aloe, Emmy G Hawkins, Arthur R Wolin, Alexander LaVeck, Connor J Hughes, Xiang Wang, Rui Zhao, Beth A J Tamburini, Gina Bouchard, Jill E Slansky, Heide L Ford

Published in

bioRxiv : the preprint server for biology. Jul 23, 2026. Epub Jul 23, 2026.

Abstract

Triple negative breast cancer (TNBC) is an aggressive form of breast cancer that remains difficult to treat despite its relatively high immunogenicity, as tumors frequently evade immune destruction through poorly understood mechanisms. Here, we discover a previously unrecognized role for Eya3 within macrophages in the tumor immune microenvironment, where its expression is elevated. Using macrophage Eya3 knockdown and conditional knockout models, we show that Eya3 depletion induces coordinated transcriptional and functional changes in macrophages, enhancing migration, antigen processing, and inflammatory signaling associated with anti-tumor immunity. Strikingly, macrophage-targeted deletion of Eya3 reprograms the immune response in TNBC, increasing CD8+ T cell infiltration, suppressing primary tumor growth, and prolonging survival. Pharmacologic inhibition of Eya3 tyrosine phosphatase activity with a novel allosteric inhibitor, LG1-34, mirrors this effect, dramatically reducing primary TNBC growth through immune-mediated mechanisms that likely act both though targeting tumor and immune cells. These findings identify Eya3 as a macrophage-intrinsic checkpoint on anti-tumor immunity, identifying a new potential vulnerability in TNBC.
Targeting Eya3 tyrosine phosphatase activity in tumor-associated macrophages reprograms the TNBC immune microenvironment and restores anti-tumor immunity, identifying a new potential therapeutic vulnerability in a cancer that has limited treatment targeted options.

PMID:
42539001
Bibliographic data and abstract were imported from PubMed on 01 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.